Expert Interview
A third look at the positive top-line results from the Phase 2 Study of barzolvolimab in chronic spontaneous urticaria.
Ticker(s): CLDXInstitution: Asthma & Allergy Associates PA
- Private practice allergist in a midwest suburban setting
- Sees 50 patients with spontaneous urticaria
- Pediatric trained but sees patients of all ages for asthma, allergic rhinitis, food allergies, and urticaria
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
